{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T09:41:43Z","timestamp":1766050903869,"version":"3.44.0"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T00:00:00Z","timestamp":1754524800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T00:00:00Z","timestamp":1754524800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-12194-1","type":"journal-article","created":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T05:11:58Z","timestamp":1754543518000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The effect of coadministration of D156844 and AR42 (REC-2282) on the survival and motor phenotype of mice with spinal muscular atrophy"],"prefix":"10.1038","volume":"15","author":[{"given":"Ashlee W.","family":"Harris","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rod C.","family":"Scott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew E. R.","family":"Butchbach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,7]]},"reference":[{"key":"12194_CR1","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1006\/nbdi.1996.0010","volume":"3","author":"TO Crawford","year":"1996","unstructured":"Crawford, T. O. & Pardo, C. A. The neurobiology of childhood spinal muscular atrophy. Neurobiol. Dis. 3, 97\u2013110 (1996).","journal-title":"Neurobiol. Dis."},{"key":"12194_CR2","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/0092-8674(95)90460-3","volume":"80","author":"S Lefebvre","year":"1995","unstructured":"Lefebvre, S. et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell 80, 155\u2013165 (1995).","journal-title":"Cell"},{"key":"12194_CR3","doi-asserted-by":"publisher","first-page":"6307","DOI":"10.1073\/pnas.96.11.6307","volume":"96","author":"CL Lorson","year":"1999","unstructured":"LorsonCL, Hahnen, E., Androphy, E. J. & Wirth, B. A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy. Proc. Natl. Acad. Sci. U S A. 96, 6307\u20136311 (1999).","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"12194_CR4","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1093\/hmg\/8.7.1177","volume":"8","author":"UR Monani","year":"1999","unstructured":"Monani, U. R. et al. A single nucleotide difference that alters splicing patterns distinguishes the SMA gene SMN1 from the copy gene SMN2. Hum. Mol. Genet. 8, 1177\u20131183 (1999).","journal-title":"Hum. Mol. Genet."},{"key":"12194_CR5","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1093\/hmg\/6.8.1205","volume":"6","author":"DD Coovert","year":"1997","unstructured":"Coovert, D. D. et al. The survival motor neuron protein in spinal muscular atrophy. Hum. Mol. Genet. 6, 1205\u20131214 (1997).","journal-title":"Hum. Mol. Genet."},{"key":"12194_CR6","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/ng0797-265","volume":"16","author":"S Lefebvre","year":"1997","unstructured":"Lefebvre, S. et al. Correlation between severity and SMN protein level in spinal muscular atrophy. Nat. Genet. 16, 265\u2013269 (1997).","journal-title":"Nat. Genet."},{"key":"12194_CR7","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1086\/515465","volume":"60","author":"PE McAndrew","year":"1997","unstructured":"McAndrew, P. E. et al. Identification of proximal spinal muscular atrophy carriers and patients by analysis of SMNT and SMNC gene copy number. Am. J. Hum. Genet. 60, 1411\u20131422 (1997).","journal-title":"Am. J. Hum. Genet."},{"key":"12194_CR8","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1093\/hmg\/9.3.333","volume":"9","author":"UR Monani","year":"2000","unstructured":"Monani, U. R. et al. The human centromeric survival motor neuron gene (SMN2) rescues embryonic lethality in Smn-\/- mice and results in a mouse with spinal muscular atrophy. Hum. Mol. Genet. 9, 333\u2013339 (2000).","journal-title":"Hum. Mol. Genet."},{"key":"12194_CR9","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1038\/71709","volume":"24","author":"HM Hsieh-Li","year":"2000","unstructured":"Hsieh-Li, H. M. et al. A mouse model for spinal muscular atrophy. Nat. Genet. 24, 66\u201370 (2000).","journal-title":"Nat. Genet."},{"key":"12194_CR10","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.nbd.2010.01.006","volume":"38","author":"M Michaud","year":"2010","unstructured":"Michaud, M. et al. Neuromuscular defects and breathing disorders in a new mouse model of spinal muscular atrophy. Neurobiol. Dis. 38, 125\u2013135 (2010).","journal-title":"Neurobiol. Dis."},{"key":"12194_CR11","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1212\/WNL.0000000000002445","volume":"86","author":"CA Chiriboga","year":"2016","unstructured":"Chiriboga, C. A. et al. Results from a phase I study of Nusinersen (ISIS-SMNRx) in children with spinal muscular atrophy. Neurology 86, 890\u2013897 (2016).","journal-title":"Neurology"},{"key":"12194_CR12","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1177\/0883073815627882","volume":"31","author":"M Hach\u00e9","year":"2016","unstructured":"Hach\u00e9, M. et al. Intrathecal injections in children with spinal muscular atrophy: Nusinersen clinical trial experience. J. Child. Neurol. 31, 899\u2013906 (2016).","journal-title":"J. Child. Neurol."},{"key":"12194_CR13","doi-asserted-by":"publisher","first-page":"3017","DOI":"10.1016\/S0140-6736(16)31408-8","volume":"388","author":"RS Finkel","year":"2016","unstructured":"Finkel, R. S. et al. Treatment of infantile-onset spinal muscular atrophy with nusinersen: A phase 2, open-label, dose-escalation study. Lancet 388, 3017\u20133026 (2016).","journal-title":"Lancet"},{"key":"12194_CR14","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1056\/NEJMoa2009965","volume":"384","author":"G Baranello","year":"2021","unstructured":"Baranello, G. et al. Risdiplam in type 1 spinal muscular atrophy. N Engl. J. Med. 384, 915\u2013923 (2021).","journal-title":"N Engl. J. Med."},{"key":"12194_CR15","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","volume":"377","author":"JR Mendell","year":"2017","unstructured":"Mendell, J. R. et al. Single-dose gene-replacement therapy for spinal muscular atrophy. N Engl. J. Med. 377, 1713\u20131722 (2017).","journal-title":"N Engl. J. Med."},{"key":"12194_CR16","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1038\/s41467-022-28653-6","volume":"13","author":"C Gubser Keller","year":"2022","unstructured":"Gubser Keller, C. et al. An orally available, brain penetrant, small molecule lowers Huntingtin levels by enhancing pseudoexon inclusion. Nat. Commun. 13, 1150 (2022).","journal-title":"Nat. Commun."},{"key":"12194_CR17","doi-asserted-by":"publisher","first-page":"3182","DOI":"10.1038\/s41467-024-47485-0","volume":"15","author":"ZL Mclean","year":"2024","unstructured":"Mclean, Z. L. et al. Splice modulators target PMS1 to reduce somatic expansion of the huntington\u2019s disease-associated CAG repeat. Nat. Commun. 15, 3182 (2024).","journal-title":"Nat. Commun."},{"key":"12194_CR18","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1186\/s13023-021-02065-z","volume":"16","author":"G Coratti","year":"2021","unstructured":"Coratti, G. et al. Motor function in type 2 and 3 SMA patients treated with nusinersen: A critical review and meta-analysis. Orphanet J. Rare Dis. 16, 430 (2021).","journal-title":"Orphanet J. Rare Dis."},{"key":"12194_CR19","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1007\/s00415-023-11560-1","volume":"270","author":"M Oskoui","year":"2023","unstructured":"Oskoui, M. et al. Two-year efficacy and safety of Risdiplam in patients with type 2 or non-ambulant type 3 spinal muscular atrophy (SMA). J. Neurol. 270, 2531\u20132546 (2023).","journal-title":"J. Neurol."},{"key":"12194_CR20","doi-asserted-by":"publisher","first-page":"e03022860","DOI":"10.1371\/journal.pone.0302860","volume":"19","author":"BD Fernandes","year":"2024","unstructured":"Fernandes, B. D. et al. Efficacy and safety of onasemnogene abeparvovec for the treatment of patients with spinal muscular atrophy type 1: Systematic review with meta-analysis. PLoS One. 19, e03022860 (2024).","journal-title":"PLoS One"},{"key":"12194_CR21","doi-asserted-by":"publisher","first-page":"100985","DOI":"10.1016\/j.vhri.2024.02.002","volume":"42","author":"A Motta-Santos","year":"2024","unstructured":"Motta-Santos, A. et al. Cost-effectiveness of technologies for the treatment of spinal muscular atrophy: A systematic review of economic studies. Value Health Reg. Issues. 42, 100985 (2024).","journal-title":"Value Health Reg. Issues"},{"key":"12194_CR22","doi-asserted-by":"publisher","first-page":"4589","DOI":"10.1007\/s12325-023-02621-y","volume":"40","author":"W Toro","year":"2023","unstructured":"Toro, W. et al. Health care resource utilization and costs for patients with spinal muscular atrophy: Findings from a retrospective US claims database analysis. Adv. Ther. 40, 4589\u20134605 (2023).","journal-title":"Adv. Ther."},{"key":"12194_CR23","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1089\/adt.2014.587","volume":"12","author":"JJ Cherry","year":"2014","unstructured":"Cherry, J. J. et al. Assays for the identification and prioritization of drug candidates for spinal muscular atrophy. Assay. Drug Dev. Technol. 12, 315\u2013341 (2014).","journal-title":"Assay. Drug Dev. Technol."},{"key":"12194_CR24","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1093\/hmg\/ddi205","volume":"14","author":"J Jarecki","year":"2005","unstructured":"Jarecki, J. et al. Diverse small-molecule modulators of SMN expression found by high-throughput compound screening: Early leads towards a therapeutic for spinal muscular atrophy. Hum. Mol. Genet. 14, 2003\u20132018 (2005).","journal-title":"Hum. Mol. Genet."},{"key":"12194_CR25","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1021\/jm061475p","volume":"51","author":"J Thurmond","year":"2008","unstructured":"Thurmond, J. et al. Synthesis and biological evaluation of novel 2,4-diaminoquinazoline derivatives as SMN2 promoter activators for the potential treatment of spinal muscular atrophy. J. Med. Chem. 51, 449\u2013469 (2008).","journal-title":"J. Med. Chem."},{"key":"12194_CR26","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1093\/hmg\/ddp510","volume":"19","author":"MER Butchbach","year":"2010","unstructured":"Butchbach, M. E. R. et al. Effects of 2,4-diaminoquinazoline derivatives on SMN expression and phenotype in a mouse model for spinal muscular atrophy. Hum. Mol. Genet. 19, 454\u2013467 (2010).","journal-title":"Hum. Mol. Genet."},{"key":"12194_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.expneurol.2014.03.005","volume":"256","author":"MER Butchbach","year":"2014","unstructured":"Butchbach, M. E. R., Singh, J., Gurney, M. E. & Burghes, A. H. M. The effect of diet on the protective action of D156844 observed in spinal muscular atrophy mice. Exp. Neurol. 256, 1\u20136 (2014).","journal-title":"Exp. Neurol."},{"key":"12194_CR28","doi-asserted-by":"publisher","first-page":"4074","DOI":"10.1093\/hmg\/ddt257","volume":"22","author":"JP Van Meerbeke","year":"2013","unstructured":"Van Meerbeke, J. P. et al. The DcpS inhibitor RG3039 improves motor function in SMA mice. Hum. Mol. Genet. 22, 4074\u20134083 (2013).","journal-title":"Hum. Mol. Genet."},{"key":"12194_CR29","doi-asserted-by":"publisher","first-page":"4084","DOI":"10.1093\/hmg\/ddt258","volume":"22","author":"RG Gogliotti","year":"2013","unstructured":"Gogliotti, R. G. et al. The DcpS inhibitor RG3039 improves survival, function and motor unit pathologies in two SMA mouse models. Hum. Mol. Genet. 22, 4084\u20134101 (2013).","journal-title":"Hum. Mol. Genet."},{"key":"12194_CR30","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1172\/JCI29562","volume":"117","author":"AM Avila","year":"2007","unstructured":"Avila, A. M. et al. Trichostatin A increases SMN expression and survival in a mouse model of spinal muscular atrophy. J. Clin. Invest. 117, 659\u2013671 (2007).","journal-title":"J. Clin. Invest."},{"key":"12194_CR31","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/sj.ejhg.5201102","volume":"12","author":"C Andreassi","year":"2004","unstructured":"Andreassi, C. et al. Phenylbutyrate increases SMN expression in vitro: Relevance for treatment of spinal muscular atrophy. Eur. J. Hum. Genet. 12, 59\u201365 (2004).","journal-title":"Eur. J. Hum. Genet."},{"key":"12194_CR32","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1038\/sj.ejhg.5201320","volume":"13","author":"C Brahe","year":"2005","unstructured":"Brahe, C. et al. Phenylbutyrate increases SMN gene expression in spinal muscular atrophy patients. Eur. J. Hum. Genet. 13, 256\u2013259 (2005).","journal-title":"Eur. J. Hum. Genet."},{"key":"12194_CR33","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1002\/ana.21449","volume":"64","author":"HL Narver","year":"2008","unstructured":"Narver, H. L. et al. Sustained improvement of spinal muscular atrophy mice treated with trichostatin A plus nutrition. Ann. Neurol. 64, 465\u2013470 (2008).","journal-title":"Ann. Neurol."},{"key":"12194_CR34","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.expneurol.2016.02.009","volume":"279","author":"MER Butchbach","year":"2016","unstructured":"Butchbach, M. E. R. et al. Protective effects of butyrate-based compounds on a mouse model for spinal muscular atrophy. Exp. Neurol. 279, 13\u201326 (2016).","journal-title":"Exp. Neurol."},{"key":"12194_CR35","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1021\/jm0303655","volume":"47","author":"Q Lu","year":"2004","unstructured":"Lu, Q. et al. Zn2+-chelating motif-tethered short-chain fatty acids as a novel class of histone deacetylase inhibitors. J. Med. Chem. 47, 467\u2013474 (2004).","journal-title":"J. Med. Chem."},{"key":"12194_CR36","doi-asserted-by":"publisher","first-page":"5530","DOI":"10.1021\/jm0503749","volume":"48","author":"Q Lu","year":"2005","unstructured":"Lu, Q., Wang, D. S., Chen, C. S., Hu, Y. D. & Chen, C. S. Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. J. Med. Chem. 48, 5530\u20135535 (2005).","journal-title":"J. Med. Chem."},{"key":"12194_CR37","doi-asserted-by":"publisher","first-page":"10374","DOI":"10.1038\/s41598-023-37496-0","volume":"13","author":"CJ Lumpkin","year":"2023","unstructured":"Lumpkin, C. J. et al. Evaluation of the orally bioavailable, 4-phenylbutyrate-tethered trichostatin A analogue AR42 in models of spinal muscular atrophy. Sci. Rep. 13, 10374 (2023).","journal-title":"Sci. Rep."},{"key":"12194_CR38","doi-asserted-by":"publisher","first-page":"45","DOI":"10.3389\/fneur.2020.00045","volume":"11","author":"N Hensel","year":"2020","unstructured":"Hensel, N., Kubinski, S. & Claus, P. The need for SMN-independent treatments of spinal muscular atrophy (SMA) to complement SMN-enhancing drugs. Front. Neurol. 11, 45 (2020).","journal-title":"Front. Neurol."},{"key":"12194_CR39","doi-asserted-by":"publisher","first-page":"105488","DOI":"10.1016\/j.nbd.2021.105488","volume":"159","author":"KM Kray","year":"2021","unstructured":"Kray, K. M., McGovern, V. L., Chugh, D., Arnold, W. D. & Burghes, A. H. M. Dual SMN inducing therapies can rescue survival and motor unit function in symptomatic D7 SMA mice. Neurobiol. Dis. 159, 105488 (2021).","journal-title":"Neurobiol. Dis."},{"key":"12194_CR40","doi-asserted-by":"publisher","first-page":"237","DOI":"10.3233\/JND-170230","volume":"4","author":"EY Osman","year":"2017","unstructured":"Osman, E. Y. et al. Analysis of Azithromycin monohydrate as a single or a combinatorial therapy in a mouse model of severe spinal muscular atrophy. J. Neuromuscul. Dis. 4, 237\u2013249 (2017).","journal-title":"J. Neuromuscul. Dis."},{"key":"12194_CR41","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.ajhg.2019.05.008","volume":"105","author":"L Torres-Benito","year":"2019","unstructured":"Torres-Benito, L. et al. NCALD antisense oligonucleotide therapy in addition to Nusinersen further ameliorates spinal muscular atrophy in mice. Am. J. Hum. Genet. 105, 221\u2013230 (2019).","journal-title":"Am. J. Hum. Genet."},{"key":"12194_CR42","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.nmd.2015.05.008","volume":"25","author":"AW Harris","year":"2015","unstructured":"Harris, A. W. & Butchbach, M. E. R. The effect of the DcpS inhibitor D156844 on the protective action of follistatin in mice with spinal muscular atrophy. Neuromuscul. Disord. 25, 699\u2013705 (2015).","journal-title":"Neuromuscul. Disord"},{"key":"12194_CR43","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1002\/jcsm.12542","volume":"11","author":"H Zhou","year":"2020","unstructured":"Zhou, H. et al. Myostatin Inhibition in combination with antisense oligonucleotide therapy improves outcomes in spinal muscular atrophy. J. Cachexia Sarcopenia Muscle. 11, 768\u2013782 (2020).","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"12194_CR44","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1093\/hmg\/ddy382","volume":"28","author":"KK Long","year":"2019","unstructured":"Long, K. K. et al. Specific Inhibition of myostatin activation is beneficial in mouse models of SMA therapy. Hum. Mol. Genet. 28, 1076\u20131089 (2019).","journal-title":"Hum. Mol. Genet."},{"key":"12194_CR45","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1093\/hmg\/ddi078","volume":"14","author":"TT Le","year":"2005","unstructured":"Le, T. T. et al. SMND7, the major product of the centromeric survival motor neuron gene (SMN2), extends survival in mice with spinal muscular atrophy and associates with full-length SMN. Hum. Mol. Genet. 14, 845\u2013857 (2005).","journal-title":"Hum. Mol. Genet."},{"key":"12194_CR46","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.nbd.2007.04.009","volume":"27","author":"MER Butchbach","year":"2007","unstructured":"Butchbach, M. E. R., Edwards, J. D. & Burghes, A. H. M. Abnormal motor phenotype in the SMND7 mouse model of spinal muscular atrophy. Neurobiol. Dis. 27, 207\u2013219 (2007).","journal-title":"Neurobiol. Dis."},{"key":"12194_CR47","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1093\/biomet\/73.1.13","volume":"73","author":"KY Liang","year":"1986","unstructured":"Liang, K. Y. & Zeber, S. L. Longitudinal data analysis using generalized linear models. Biometrika 73, 13\u201322 (1986).","journal-title":"Biometrika"},{"key":"12194_CR48","doi-asserted-by":"publisher","first-page":"108360","DOI":"10.1016\/j.reprotox.2023.108360","volume":"118","author":"L Mueller","year":"2023","unstructured":"Mueller, L., Barrow, P., Jacobsen, B., Ebeling, M. & Weinbauer, G. Reproductive findings in male animals exposed to selective survival of motor neuron 2 (SMN2) gene splicing-modifying agents. Reprod. Toxicol. 118, 108360 (2023).","journal-title":"Reprod. Toxicol."},{"key":"12194_CR49","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1177\/01926233231180179","volume":"51","author":"D Theil","year":"2023","unstructured":"Theil, D. et al. Neurofilament light chain: a translational safety biomarker for drug-induced peripheral neurotoxicity. Toxicol. Pathol. 51, 135\u2013147 (2023).","journal-title":"Toxicol. Pathol."},{"key":"12194_CR50","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1002\/emmm.201202305","volume":"5","author":"JJ Cherry","year":"2013","unstructured":"Cherry, J. J. et al. Enhancement of SMN protein levels in a mouse model of spinal muscular atrophy using novel drug-like compounds. EMBO Mol. Med. 5, 1103\u20131118 (2013).","journal-title":"EMBO Mol. Med."},{"key":"12194_CR51","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1126\/science.1250127","volume":"345","author":"NA Naryshkin","year":"2014","unstructured":"Naryshkin, N. A. et al. SMN2 splicing modifiers improve motor function and longevity in mice with spinal muscular atrophy. Science 345, 688\u2013693 (2014).","journal-title":"Science"},{"key":"12194_CR52","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1093\/hmg\/ddw062","volume":"25","author":"X Zhao","year":"2016","unstructured":"Zhao, X. et al. Pharmacokinetics, pharmacodynamics and efficacy of a small-molecule SMN2 splicing modifier in mouse models of spinal muscular atrophy. Hum. Mol. Genet. 25, 1885\u20131899 (2016).","journal-title":"Hum. Mol. Genet."},{"key":"12194_CR53","doi-asserted-by":"publisher","first-page":"6501","DOI":"10.1021\/acs.jmedchem.8b00741","volume":"61","author":"H Ratni","year":"2018","unstructured":"Ratni, H. et al. Discovery of risdiplam, a selective survival of motor neuron-2 (SMN2) gene splicing modifier for the treatment of spinal muscular atrophy (SMA). J. Med. Chem. 61, 6501\u20136517 (2018).","journal-title":"J. Med. Chem."},{"key":"12194_CR54","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1038\/s41467-017-01559-4","volume":"8","author":"M Sivaramakrishnan","year":"2017","unstructured":"Sivaramakrishnan, M. et al. Binding of SMN2 pre-mRNA-protein complex elicits specificity for small molecule splicing modifiers. Nat. Commun. 8, 1476 (2017).","journal-title":"Nat. Commun."},{"key":"12194_CR55","doi-asserted-by":"publisher","first-page":"17472","DOI":"10.1038\/s41598-020-74346-9","volume":"10","author":"S Ando","year":"2020","unstructured":"Ando, S. et al. Discovery of a CNS penetrant small molecule SMN2 splicing modulator with improved tolerability for spinal muscular atrophy. Sci. Rep. 10, 17472 (2020).","journal-title":"Sci. Rep."},{"key":"12194_CR56","doi-asserted-by":"publisher","first-page":"3415","DOI":"10.1093\/hmg\/ddt191","volume":"22","author":"F Farooq","year":"2013","unstructured":"Farooq, F. et al. Celecoxib increases SMN and survival in a severe spinal muscular atrophy mouse model via p38 pathway activation. Hum. Mol. Genet. 22, 3415\u20133424 (2013).","journal-title":"Hum. Mol. Genet."},{"key":"12194_CR57","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1111\/j.1476-5381.2012.01829.x","volume":"166","author":"YY Hsu","year":"2012","unstructured":"Hsu, Y. Y. et al. Triptolide increases transcript and protein levels of survival motor neurons in human SMA fibroblasts and improves survival in SMA-like mice. Br. J. Pharmacol. 166, 1114\u20131126 (2012).","journal-title":"Br. J. Pharmacol."},{"key":"12194_CR58","doi-asserted-by":"publisher","first-page":"4414","DOI":"10.1007\/s12035-018-1379-z","volume":"56","author":"S de la Fuente","year":"2019","unstructured":"de la Fuente, S., Sansa, A., Periyakaruppiah, A., Garcera, A. & Soler, R. M. Calpain Inhibition increases SMN protein in spinal cord motoneurons and ameliorates the spinal muscular atrophy phenotype in mice. Mol. Neurobiol. 56, 4414\u20134427 (2019).","journal-title":"Mol. Neurobiol."},{"key":"12194_CR59","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.phrs.2016.05.023","volume":"111","author":"YT Tseng","year":"2016","unstructured":"Tseng, Y. T., Chen, C. S., Jong, Y. J., Chang, F. R. & Lo, Y. C. Loganin possess neuroprotective properties, restores SMN protein and activates protein synthesis positive regulator akt\/mtor in experimental models of spinal muscular atrophy. Pharmacol. Res. 111, 58\u201375 (2016).","journal-title":"Pharmacol. Res."},{"key":"12194_CR60","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1038\/s41598-018-38208-9","volume":"9","author":"EY Osman","year":"2019","unstructured":"Osman, E. Y. et al. Intraperitoneal delivery of a novel drug-like compound improves disease severity in severe and intermediate mouse models of spinal muscular atrophy. Sci. Rep. 9, 1633 (2019).","journal-title":"Sci. Rep."},{"key":"12194_CR61","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1093\/hmg\/ddp030","volume":"18","author":"CR Heier","year":"2009","unstructured":"Heier, C. R. & DiDonato, C. J. Translational readthrough by the aminoglycoside geneticin (G418) modulates SMN stability in vitro and improves motor function of SMA mice in vivo. Hum. Mol. Genet. 18, 1310\u20131322 (2009).","journal-title":"Hum. Mol. Genet."},{"key":"12194_CR62","doi-asserted-by":"publisher","first-page":"3906","DOI":"10.1093\/hmg\/ddp333","volume":"18","author":"VB Mattis","year":"2009","unstructured":"Mattis, V. B., Ebert, A. D., Fosso, M. Y., Chang, C. W. & Lorson, C. L. Delivery of a read-through inducing compound, TC007, lessens the severity of a SMA animal model. Hum. Mol. Genet. 18, 3906\u20133913 (2009).","journal-title":"Hum. Mol. Genet."},{"key":"12194_CR63","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/1471-2202-10-142","volume":"10","author":"VB Mattis","year":"2009","unstructured":"Mattis, V. B., Fosso, M. Y., Chang, C. W. & Lorson, C. L. Sucutaneous administration of TC007 reduces disease severity in an animal model of SMA. BMC Neurosci. 10, 142 (2009).","journal-title":"BMC Neurosci."},{"key":"12194_CR64","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.neulet.2012.07.024","volume":"525","author":"VB Mattis","year":"2012","unstructured":"Mattis, V. B., Chang, C. W. T. & Lorson, C. L. Analysis of a read-through promoting compound in a severe mouse model of spinal muscular atrophy. Neurosci. Lett. 525, 72\u201375 (2012).","journal-title":"Neurosci. Lett."},{"key":"12194_CR65","doi-asserted-by":"publisher","first-page":"e88427","DOI":"10.1172\/jci.insight.88427","volume":"1","author":"MB Abera","year":"2016","unstructured":"Abera, M. B. et al. ML372 blocks SMN ubiquitination and improves spinal muscular atrophy pathology in mice. JCI Insight. 1, e88427 (2016).","journal-title":"JCI Insight"},{"key":"12194_CR66","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1038\/s41598-018-20219-1","volume":"8","author":"D Sapaly","year":"2018","unstructured":"Sapaly, D. et al. Small-molecule Flunarizine increases SMN protein in nuclear Cajal bodies and motor function in a mouse model of spinal muscular atrophy. Sci. Rep. 8, 2075 (2018).","journal-title":"Sci. Rep."},{"key":"12194_CR67","doi-asserted-by":"publisher","first-page":"55","DOI":"10.3389\/fmolb.2020.00055","volume":"7","author":"D Sapaly","year":"2020","unstructured":"Sapaly, D. et al. The small-molecule Flunarizine in spinal muscular atrophy patient fibroblasts impacts on the Gemin components of the SMN complex and TDP43, an RNA-binding protein relevant to motor neuron diseases. Front. Mol. Biosci. 7, 55 (2020).","journal-title":"Front. Mol. Biosci."},{"key":"12194_CR68","doi-asserted-by":"publisher","first-page":"18960","DOI":"10.1038\/s41598-022-23703-x","volume":"12","author":"P Delers","year":"2022","unstructured":"Delers, P. et al. A link between Agrin signalling and Cav3.2 at the neuromuscular junction in spinal muscular atrophy. Sci. Rep. 12, 18960 (2022).","journal-title":"Sci. Rep."},{"key":"12194_CR69","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1093\/hmg\/ddq021","volume":"19","author":"M Bowerman","year":"2010","unstructured":"Bowerman, M., Beauvais, A., Anderson, C. L. & Kothary, R. Rho-kinase inactivation prolongs survival of an intermediate SMA mouse model. Hum. Mol. Genet. 19, 1468\u20131478 (2010).","journal-title":"Hum. Mol. Genet."},{"key":"12194_CR70","doi-asserted-by":"publisher","first-page":"308","DOI":"10.3389\/fnmol.2018.00308","volume":"11","author":"R Schellino","year":"2018","unstructured":"Schellino, R., Boido, M., Borsello, T. & Vercelli, A. Pharmacological c-Jun NH2-terminal kinase (JNK) pathway Inhibition reduces severity of spinal muscular atrophy disease in mice. Front. Mol. Neurosci. 11, 308 (2018).","journal-title":"Front. Mol. Neurosci."},{"key":"12194_CR71","doi-asserted-by":"publisher","first-page":"3223","DOI":"10.1038\/s41419-017-0086-4","volume":"20178","author":"A Piras","year":"2017","unstructured":"Piras, A. et al. Inhibition of autophagy delays motoneuron degeneration and extends lifespan in a mouse model of spinal muscular atrophy. Cell. Death Dis. 20178, 3223 (2017).","journal-title":"Cell. Death Dis."},{"key":"12194_CR72","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.2119\/molmed.2012.00056","volume":"18","author":"M Murdocca","year":"2012","unstructured":"Murdocca, M. et al. IPLEX administration improves motor neuron survival and ameliorates motor functions in a severe mouse model of spinal muscular atrophy. Mol. Med. 18, 1076\u20131085 (2012).","journal-title":"Mol. Med."},{"key":"12194_CR73","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.ebiom.2018.04.024","volume":"31","author":"LM Walter","year":"2018","unstructured":"Walter, L. M. et al. Interventions targeting glucocorticoid-Kr\u00fcppel-like factor 15-branched-chain amino acid signaling improve disease phenotypes in spinal muscular atrophy mice. EBioMedicine 31, 226\u2013242 (2018).","journal-title":"EBioMedicine"},{"key":"12194_CR74","doi-asserted-by":"publisher","first-page":"e0166803","DOI":"10.1371\/journal.pone.0166803","volume":"11","author":"M Liu","year":"2016","unstructured":"Liu, M., Hammers, D. W., Barton, E. R. & Sweeney, H. L. Activin receptor type IIB Inhibition improves muscle phenotype and function in a mouse model of spinal muscular atrophy. PLoS One. 11, e0166803 (2016).","journal-title":"PLoS One"},{"key":"12194_CR75","doi-asserted-by":"crossref","unstructured":"Kordala, A. J. et al. PRMT inhibitor promotes SMN2 exon 7 inclusion and synergizes with Nusinersen to rescue SMA mice. EMBO Mol. Med (2023).","DOI":"10.15252\/rc.2023679961"},{"key":"12194_CR76","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.bbrc.2009.11.148","volume":"391","author":"MER Butchbach","year":"2010","unstructured":"Butchbach, M. E. R. et al. Effect of diet on the survival and phenotype of a mouse model for spinal muscular atrophy. Biochem. Biophys. Res. Commun. 391, 835\u2013840 (2010).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"12194_CR77","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1002\/acn3.50920","volume":"6","author":"MO Deguise","year":"2019","unstructured":"Deguise, M. O., Chehade, L., Tierney, A., Beauvais, A. & Kothary, R. Low fat diets increase survival of a mouse model of spinal muscular atrophy. Ann. Clin. Transl Neurol. 6, 2340\u20132346 (2019).","journal-title":"Ann. Clin. Transl Neurol."},{"key":"12194_CR78","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.jneumeth.2006.11.002","volume":"161","author":"MER Butchbach","year":"2007","unstructured":"Butchbach, M. E. R., Edwards, J. D., Schussler, K. R. & Burghes, A. H. M. A novel method for oral delivery of compounds to the neonatal SMND7 model of spinal muscular atrophy. J. Neurosci. Methods. 161, 285\u2013290 (2007).","journal-title":"J. Neurosci. Methods"},{"key":"12194_CR79","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.bbr.2011.03.007","volume":"221","author":"A Jahn-Eimermacher","year":"2011","unstructured":"Jahn-Eimermacher, A., Lasarzik, I. & Raber, J. Statistical analysis of latency outcomes in behavioral experiments. Behav. Brain Res. 221, 271\u2013275 (2011).","journal-title":"Behav. Brain Res."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-12194-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-12194-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-12194-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T15:41:02Z","timestamp":1757346062000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-12194-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,7]]},"references-count":79,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["12194"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-12194-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"type":"electronic","value":"2045-2322"}],"subject":[],"published":{"date-parts":[[2025,8,7]]},"assertion":[{"value":"17 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"28866"}}